Materials and Methods

Animals
Four-week-old male Sprague Dawley (n=142), prehypertensive SHR (n=8), and normotensive Wistar-Kyoto (n=8) rats were used in this study. The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and the Animals (Scientific Procedures) Act 1986 (United Kingdom). An expanded Materials and Methods section is available in the online-only Data Supplement.
Results
BNP Decreases Heart Rate Responses to Right Stellate Stimulation In Vitro and Evoked Norepinephrine Release
We asked whether BNP could directly regulate the heart rate responses to cardiac sympathetic nerve stimulation in an isolated innervated double atria preparation that was decentralized and devoid of circulating factors. Stimulation of the right stellate ganglion produced a frequency-dependent increase in heart rate ( Figure 1Ai ). Addition of 250 nmol/L BNP caused no significant changes in baseline heart rate (control, 309±16 bpm; BNP, 311±14 bpm; P=0.91, paired t test), whereas it caused a significantly reduced heart rate response to nerve stimulation across all frequencies when compared with control stimulations (n=10; Figure 1Ai and 1Aii). There was a trend for a lower concentration (100 nmol/L) at 1 and 3 Hz to also decrease sympathetic responsiveness ( Figure S1 in the online-only Data Supplement).
To test whether the attenuated heart rate response to nerve stimulation caused by BNP was a result of decreased neurotransmission, we directly measured the level of [ 3 H]-norepinephrine release in response to field stimulation of right atrial preparations. Because only 250 nmol/L reached a statistically reduced heart rate response to nerve stimulation, we chose to use 250 nmol/L on the [ 3 H]-norepinephrine release experiment. There was no difference between the first (S1) and second (S2) field stimulation at 5 Hz without BNP (S1, +1.68±0.12%; S2, +1.64±0.15%; n=4; Figure 1Bi and 1Biii), indicating no significant time-dependent changes. However, as we expected, BNP (250 nmol/L) produced ≈43% reduction in [ 3 H]-norepinephrine release in response to 5-Hz field stimulation (S1, +1.75±0.25%; S2, +0.99±0.23%; n=6; P<0.05, 1-way ANOVA; Figure 1Bii and 1Biii).
BNP Reduces Neuronal Calcium Current and Intracellular-Free Calcium Transients in Cardiac Sympathetic Neurons
We next assessed whether BNP would also affect calcium signaling in isolated stellate neurons. Antityrosine hydroxylase immunofluorescence staining from fixed cultured stellate neuron is shown in Figure 2A . Virtually all the neurons had tyrosine hydroxylase-positive expression, confirming that the neurons were sympathetic. The neuronal calcium current was measured using the whole cell configuration of the patch-clamp technique. The calcium current was significantly reduced by −16.7±5.9% (P<0.05; n=6) and −15.2±3.2% (P<0.05; n=3) after 10-minute exposure to 100 and 250 nmol/L BNP, respectively ( Figure 2Ci . BNP was introduced at 7 minutes after the first high K + stimulation (S1; Figure 2Ci ). After 10 minutes of treatment, neurons were stimulated again (S2) in the presence of BNP. In a concentration-dependent manner, BNP (1, 10, 50, 100, 250 nmol/L) caused ≈2% to 22% decrease in [Ca 2+ ] i evoked by high K + depolarization from cardiac sympathetic neurons. This was statistically significant at 100 and 250 nmol/L (Figure 2Cii ), however, these concentrations did not affect basal [Ca 2+ ] i (Figure 2Ciii ). There was no significant difference between 100 and 250 nmol/L BNP on [Ca 2+ ] i , so we chose to use 100 nmol/L in the cellular experiments.
Pharmacological Manipulation of NPR-A/cGMP/ PKG Pathway
Several putatively selective inhibitors of the NPR-A/cGMP/ PKG pathway were used to further elucidate the signal transduction pathway (Figure 3 ). Pretreatment of NPR-A inhibitor Isatin (1H-indole-2,3-dione, 10 μmol/L) or the PKG inhibitor (RP-8-Br-PET-cGMP, 5 μmol/L) almost completely abolished the action of 100 nmol/L BNP on the [Ca 2+ ] i . cAMP-dependent protein kinase inhibitor (1 μmol/L) alone reduced the [Ca 2+ ] i transient (−12.5±3.2% compared with control). However, BNP maintained its ability to reduce the depolarization evoked [Ca 2+ ] i transient in the presence of the protein kinase inhibitor, suggesting protein kinase was not critical to the pathway downstream after NPR-A activation.
Phosphodiesterases play a major role in cell signaling by hydrolyzing cAMP and cGMP. 26 ] i transient in the presence of IBMX at both concentrations ( Figure 3C ). In the nervous system, the isoforms PDE2 and PDE3 are dominant. 20, 27 Therefore, the PDE3 inhibitor Milrinone (10 μmol/L) or PDE2 inhibitor Bay60-7550 (1 μmol/L) was introduced during BNP stimulation. In the presence of Milrinone, BNP still maintained its inhibition on the [Ca 2+ ] i transient ( Figure 3D ). Interestingly, application of BNP in the presence of Bay60-7550 further reduced the [Ca 2+ ] i transient compared with BNP alone ( Figure 3D ).
BNP Does Not Affect Intracellular cAMP Level
Real-time measurements of intracellular cAMP concentration in living cardiac sympathetic neurons were first performed using ratiometric fluorescence resonance energy transfer (FRET) imaging in the presence of BNP. Depolarizing the neuron with 50 mmol/L KCl led to a decrease in yellow fluorescent protein emission ( Figure 4A , yellow trace) and a concomitant increase in cyan fluorescent protein emission ( Figure 4A , cyan trace), resulting in an increase of the ratiometric FRET signal (ΔR/R 0 ). This is consistent with an increase in cAMP accumulation. 28 Neurons were stimulated again in the presence of 100 nmol/L BNP ( Figure 4A and 4B). BNP caused no significant changes in the FRET signal ( Figure 4C ). Moreover, in the unstimulated neuron, 100 and 250 nmol/L BNP did not cause a significant decrease in the Figure 4D ). PDE2 inhibitor Bay60-7550 (1 μmol/L) also did not significantly affect the unstimulated FRET signal ( Figure 4E, n=4) . To show that the sensitivity of the FRET sensor was intact, application of IBMX (100 μmol/L) caused a marked rise in cAMP ( Figure 4E ). 29 and reduced after application with PDE2A inhibition in normal cells, we measured the PDE2A activity in these stellate ganglia. As shown in Figure 5A , PDE2 activity (expressed as the cGMP-PDE2 hydrolytic activity) was ≈60% higher in the SHR when compared with the Wistar-Kyoto rats (Figure 5Ai ). Moreover, it was ≈90% greater in PDE2A transduced ganglia ( Figure 5Aii ) compared with the empty treated group, as we attempted to mimic the SHR PDE levels.
Effect of PDE2A Overexpression in Presence of BNP
Western Blotting and cGMP Production
Gene transfer of empty or Ad.PDE2A to the isolated stellate ganglia was confirmed with Western blot analysis. PDE2A. mCherry expression (127 KDa, with anti-PDE2A antibody) was significantly enhanced in Ad.PDE2A transduced stellate ganglia tissue when compared with those transduced with the empty virus alone ( Figure 5B ). We detected no difference in endogenous levels of PDE2A (100 KDa) protein in either group (n=5 in each group; Figure S3 ). cGMP production ( Figure 5C ) was markedly enhanced (≈3-fold) after application of 250 nmol/L BNP in the transduced empty virus stellate ganglia tissue. However, in the presence of BNP, overexpression of Ad.PDE2A reduced cGMP accumulation by ≈60% compared with the empty control transduced tissue. This suggests that PDE2A is responsible for the degradation of newly synthesized BNP-activated cGMP.
PDE2A Overexpression Increases Neuronal Calcium Current and Intracellular-Free Calcium Transients
Fluorescence microscopy detected mCherry expression in stellate neurons after transduction with the empty virus or Ad.PDE2A ( Figure 6B ). Because all neurons did not express mCherry, we only selected the transduced neurons to measure calcium current and intracellular calcium transients. The calcium current was significantly reduced by ≈21% after 10-minute exposure to 100 nmol/L BNP (Figure 6Ai ) in the empty transduced group. Whereas in Ad.PDE2A transduced neurons, BNP failed to affect the calcium current ( Figure 6Aii ). This response was recovered after inhibition of PDE2 by Bay60-7550 (1 μmol/L) in Ad.PDE2A transduced neurons (reduced ≈12%, Figure 6Aiii ).
As we expected, [Ca 2+ ] i transients were significantly enhanced (≈32%) in Ad.PDE2A transduced neurons when compared with the empty control (Figure 6Ci 
Evoked Norepinephrine Release
We then investigated whether overexpression of PDE2A affected neurotransmitter release. 
Discussion
In this study, we provide some insight into the inhibitory action of BNP signaling on cardiac sympathetic transmission and excitability. We found that BNP reduces [Ca 2+ ] i transients in a concentration-dependent manner and also decreases the calcium current in primary cultured stellate cells. This translated into a reduction in neurotransmitter release and heart rate responsiveness to direct sympathetic nerve stimulation in vitro. The inhibitory action of BNP on the [Ca 2+ ] i transient is regulated by the NPR-A/cGMP/PKG pathway, where PDE2 modulates the hydrolysis of cGMP that is synthesized by the addition of BNP (Figure 8 ). Where PDE2A activity is elevated in stellate neurons, it is conceivable that it provides a brake against the inhibitory action of BNP on sympathetic transmission.
BNP Suppresses Cardiac Sympathetic Nerve Activity
Our findings agree with the generally held view that NPs afford beneficial cardiac and hemodynamic effects. 16 NPs have been viewed as a compensatory neurohormonal system that is upregulated in the setting of heart failure 30 and hypertension. 31 Specifically, infusion of BNP decreases norepinephrine spillover in patients with heart failure, 17 and in experimental animal models, atrial NP produces a direct depressant action on sympathetic nerve function by reducing both cardiac output and arterial blood pressure. 32 Atrial NP also augments cardiac parasympathetic nerve activity in humans 33 and rats, 34 and of interest, NP mimic the action of the nitric oxide-cGMP pathway in facilitating acetylcholine release. 35 Moreover, elevating cGMP levels with nitric oxide inhibits calcium transients and sympathetic neurotransmission, indicating a pivotal role for this cyclic nucleotide in the modulation of neurotransmission. 21, 22, 29 In this work, we found that BNP decreased norepinephrine release from atrial preparations in response to field stimulation and also significantly reduced the heart rate ] i transient is only affected by membrane calcium entry. The endoplasmic reticulum and mitochondria also regulate intracellular calcium (ie, also sensitive to nitric oxidecGMP levels) after cellular depolarization with KCl. 29, 36 Whether BNP directly affects these subcellular organelles has not been established.
The receptor for BNP, NPR-A ,is expressed on cells in many different tissues of various organ systems. 37 NPR-A is linked to particulate guanylate cyclase, a unique intracellular guanylate cyclase-catalytic domain for this receptor that mediates the biological actions through the production of cGMP as a second messenger. 38 This was confirmed by direct measurement of cGMP levels that were increased with BNP in stellate ganglia tissue. Our finding that NPR-A blockade prevents BNP-mediated reductions in peak [Ca 2+ ] i gives functional evidence for NPR-A binding mediating the effects of BNP. Failure of BNP to reduce Ca 2+ transients when the PKG blocker was added confirmed that BNP evoked reductions in [Ca 2+ ] i transients were most likely dependent on PKGmediated inhibition of voltage-gated Ca 2+ channels. This is consistent with the proposal that BNP activates a PKG signaling pathway involved in the inhibition of neurotransmission in the dorsal root ganglion. 39 PKG is known to be activated by cGMP, the activity of which is also regulated by phosphodiesterases. 26 Our results differ from a previous study that highlights a pivotal role for protein kinase in mediating the paradoxical proadrenergic effects of BNP. Here, it was shown that PKG-mediated inhibition of cAMP hydrolysis by PDE3 caused a subsequent Ca 2+ -dependent release of norepinephrine. 20 This conclusion was based on experiments performed on a PC12 cell line in the absence of neuronal membrane depolarization. In contrast, our results in depolarized cardiac sympathetic neurons showed that inhibition of PDE3 and protein kinase did not disrupt the effect of BNP on the [Ca 2+ ] i transient. Moreover, BNP had virtually no effect on the FRET measured cAMP under either basal conditions or during periods of stimulation. In addition, the inhibitory effect of BNP on the [Ca 2+ ] i transient was augmented by blocking PDE2, but prevented by inhibition of PKG. This result is consistent with others who report that in primary neuronal cultures (from the brain), inhibition of PDE2 enhances cGMP levels, whereas cAMP levels are unaffected. 40 
The Role of PDE2 in Cardiac Neural Signaling
PDE2A has been shown to play important roles in many signal transduction pathways as a regulator of both cGMP and cAMP levels. [40] [41] [42] [43] PDE2 is markedly upregulated in heart failure and blunts β-adrenergic responses by hydrolysis of cAMP in cardiomyocytes. 24, 44 This provides a negative crosstalk mechanism between cAMP and cGMP signaling pathways. In cardiac stellate ganglia, we observed that the action of BNP is regulated by PDE2A activity. We also show that PDE2A activity is upregulated in the SHR stellate ganglia. This in turn depletes cGMP and reduces PKG activity, resulting in decreased inhibition of voltage-gated calcium channels and intracellular calcium transients. Our results agree with others that PDE2 predominantly hydrolyses cGMP rather than cAMP in neurons. 45, 46 The difference between the myocyte and neuron may well be related to the microdomain organization of PDE2A splice variants (PDE2A1-3) expressed in difference species. 47 The inhibitory action of BNP on the calcium current/[Ca 2+ ] i and neurotransmission was prevented by overexpression of PDE2A. This was associated with ≈60% reduction in cGMP, suggesting that PDE2A plays a key role in modulating the efficacy of BNP. Furthermore, blockade of overexpressed PDE2A re-established the action of BNP. Our data suggest a possible site of regulation on PDE2A signaling, where BNP might fail in hypertension, resulting in excessive sympathetic activity.
Perspectives
Plasma levels of BNP increase because of chronic stretch in heart failure 3 and can rise by ≤30-fold in severe cases. 48 The finding that BNP reduced sympathetic outflow from stimulated stellate ganglion neurons is suggestive of a compensatory protective role against sympathetic overactivity, implicated in Figure 8 . Diagram illustrating the potential signal transduction pathways mediated by B-type natriuretic peptide (BNP) in depolarized stellate neurons. BNP binds to the natriuretic peptide receptor A (NPR-A) and stimulates particulate guanylyl cyclase (pGC). Newly synthesized cGMP activates phosphodiesterase 2 (PDE2) to degrade cGMP, but not cAMP, and thus limits the increase in protein kinase G (PKG) activity. Moreover, PKG inhibits calcium current by phosphorylating voltage-gated calcium channels (VGCCs) and reduces the intracellular calcium transient. This in turn decreases norepinephrine release from synaptic vesicles and reduces the heart rate response to sympathetic stimulation. In addition, elevated intracellular calcium triggers the activation of adenylate cyclase (AC) via calmodulin (CaM) and produces cAMP. cAMP activates cAMP-dependent protein kinase (PKA), thus phosphorylation of calcium channel.
by guest on April 3, 2017 http://hyper.ahajournals.org/ Downloaded from the pathophysiology of both hypertension 49 and heart failure. 50 Our findings suggest that contrary to the proposal of Chan et al, 20 the lack of clinical efficacy of BNP is not attributable to the proexocytotic nature of the BNP pathway. Instead, we propose that the usual ability of BNP to modulate Ca 2+ signaling and neurotransmission in sympathetic neurons is via a cGMP-PDE2A pathway. BNP has a diverse action and thus an integrative view of this neurohormone at a systemic level must also be taken into account if it is to be viewed as a targeted therapy in vivo. Moreover, whether the BNP-cGMP-PDE2A pathway is actually impaired in hypertensive and heart failure models remains to be firmly established.
Supplement Methods
Solutions and Materials. Unless otherwise stated, all chemicals were purchased from Sigma (St. Louis, MO) and Invitrogen (Eugen, OR). Tyrode solution for measuring intracellular calcium and cAMP concentration: (in mmol/L) 135 NaCl, 4.5 KCl, 11 Glucose, 1 MgCl 2 , 2 CaCl 2 and 20 HEPES (pH 7.4). Tyrode solution for norepinephrine release and heart rate response experiments contained (in mmol/L) 120 NaCl, 4.7 KCl, 1.2 MgSO 4 , 25 NaHCO 3 , 2 CaCl 2 , 1.2 KH 2 PO 4 and 11 glucose, and was aerated with 95% O 2 /5% CO 2 (pH 7.4). Fluorescent dye, Fura-2/AM was obtained from Molecular Probes (Eugene, OR). L-15 blocking medium: 96.8% L-15 medium supplemented with 0.6% D-(+)-Glucose solution, 2 mmol/L L-glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, 10% Fetal bovine serum. Plating medium: 90% L-15 medium supplemented with 24 mmol/L NaHCO 3 , 38 mmol/L Glucose, 50 units/ml penicillin, 50 μg/ml streptomycin, 50 ng/ml Nerve growth factor, 10% Fetal bovine serum.
Heart Rate Responsiveness in Isolated Double Atria and Right Stellate Ganglion
Preparation. The spontaneously beating atria with intact sympathetic innervation were isolated and transferred to a preheated (37 ± 0.2 °C), continuously oxygenated, water-jacketed organ bath containing 100 ml Tyrode solution. The method for dissecting and measuring responses to sympathetic nerve stimulation (SNS) has been described previously (1) . The stellate was stimulated at 1, 3, 5 and 7 Hz, (20 V, 1 ms pulse duration for 30 s). Drugs were applied directly to the organ bath and incubated until a consistent response to SNS was obtained. The spontaneously beating right atrium was isolated and transferred to a preheated (37 ± 0.2 °C), continuously oxygenated, water-jacketed organ bath containing 3 ml Tyrode solution where the atrium was pinned flat on a silver stimulating electrode. The method for determining the local release of 3 H-NE to field stimulation 5 Hz (15 V, 1 ms pulse width, for 1 min) was identical to that which we have previously described (2) .
Primary Cultures of Dissociated Sympathetic Neurons. Sympathetic neurons were isolated using a previously published method (3). The stellate ganglia were removed from 4-wk -old SD rats and isolated enzymatically with collagenase and trypsin. Experiments were performed 2-3 days after plating.
Adenovirus Vector Transduction.
A human cytomegalovirus (CMV) vector expressing PDE2A and red fluorescent protein mCherry (Ad.CMV.PDE2A-mCherry) was transduced to cultured cardiac sympathetic neurons (for calcium current and transient measurement) or isolated stellate ganglia tissue (for western blot, cGMP and PDE2 activity assay). An adenoviral vector expressing only mCherry (Ad.CMV-mCherry) was used as a control for comparing the effect of viral transduction. 5×10 7 pfu of adenoviral vector was used to infect neurons or ganglia in a 4 well plate (1.9 cm 2 /well, Nunc, Denmark). The virus containing medium was left in the well a maximum of 12 hours before changing to fresh medium. Experiments were performed after 3 days following gene transfer except the patch clamp recording performed at 12-22 hours.
For the evoked norepinephrine release experiment, targeted percutaneous gene transfer to the right atrium was performed under halothane (Fluothane, Concord Pharmaceuticals Ltd) or isoflurane (Isocare, Animalcare Ltd) anesthesia (4% for induction and 2% to 3% for maintenance in 100% O 2 ), using a technique similar to that described previously for the guinea pig (4) . Animals received an injection of 1×10 9 pfu of Ad.CMV.PDE2A-mCherry or Ad.CMV-mCherry in 300 μl of PBS. Molecular and physiological phenotyping was performed 4 days after the injection. Real-time Imaging of cAMP. Intracellular cAMP was imaged using FRET-based cAMP sensor H30 as described previously (6) . Neuron expression of the sensor was achieved by recombinant adenoviral vector transfer. 8x10 6 pfu/ml virus was used to infect neurons. After three days infection, cells were imaged on an inverted Nikon microscope connected to an OptoLED fluorescence imaging system (Cairn Research Ltd) equipped with a 40x, oilimmersion objective, a CoolSNAP HQ2 digital CCD camera (Photometrics), and a beamsplitter (DV2, Photometrics) including the specific set of emission filters for CFP and YFP acquisition (dichroic mirror 505DCXR, YFP emission of 535 nm, and CFP emission of 480 nm; Chroma Technology Corp.). FRET changes were measured as changes in the ratio between 480/535-nm fluorescent emission intensities after background subtraction upon excitation at 430 nm. For dynamic FRET changes, the kinetic of the 480/535-nm emission intensity ratio was plotted against time, and the mean FRET response was expressed as the percentage of ΔR/R 0 , in which ΔR = R − R 0 . R 0 is the ratio at time = 0 second, and R is the ratio at time = t seconds.
Patch-clamp
Immunofluorescence and Western Blotting. Cultured primary neurons were fixed in acetone/methanol for 10 min, followed by antigen blocking in 1% BSA and with primary antibody against tyrosine hydroxylase (TH, mouse mAb, 1:1000, Sigma) in 1% BSA overnight at -4C°. Signals were visualized with anti-mouse antibody conjugated to Alexa-594 (1:1000, Molecular Probes). Nuclear staining was performed with 4',6-Diamidino-2-Phenylindole (DAPI, Sigma). Protein extraction and Western blotting performed as described previously in detail (3). The following primary antibodies were used: anti-PDE2A (rabbit pAb, 1:500, Thermo Pierce), anti-mCherry (rabbit pAb, 1:1000, Abcam) anti β-actin (rabbit pAb, 1:2500, Abcam). PDE2 Activity assay. Stellate ganglia from SD rats were dissected and put in 4 well plate which contain 5×10 7 pfu of adenoviral vector in 1 ml plating medium that was kept at 37ºC in 5% CO 2 . The virus containing medium was left in the well for a maximum of 12 hours before changing to fresh medium. After 3 days of gene transfer, some wells incubated in the medium which contain 250 nmol/L BNP for 20 min at 37ºC, 5% CO 2 and terminated the reaction by rapidly frozen the tissues in liquid nitrogen. Stellate ganglia from SHR and WKY rats were dissected and directly frozen in liquid nitrogen. Phosphodiesterase activity was measured using the Phosphodiesterase Activity Assay Kit (abcam, ab139460). Tissues were homogenized in lysis buffer and protease inhibitor cocktail (sigma), centrifuged at 10,000 rpm (4ºC, 10 min) in a microfuge. Tissue homogenates were desalted using Zeba Spin Desalting Columns (Thermo scientific). PDE2 activity is shown as pmol 5'-GMP produced per mg of protein per min inhibited by 1 µmol/L BAY 60-7550, a highly specific PDE2 inhibitor.
Measurement of tissue cGMP levels. Infected stellate ganglia tissue were prepared the same as for the PDE2 activity assay. Tissues were homogenized in 0.1M HCl. Precipitated proteins were removed by centrifugation, and the supernatant was collected for the cGMP assay Measurement of cGMP levels using cGMP Direct Immunoassay Kit (Abcam, ab65356) according to the manufacturer's instructions. Results are shown as pmol cGMP per mg protein.
Statistical analysis. Data were expressed as means ± SEM. All statistical calculations were performed using the SigmaPlot 12.5 software package (Systat Software Inc.). For comparison of two groups, an unpaired t-test was performed, or a Mann-Whitney Rank Sum Test if the data were not normally distributed. To compare more than two groups, One-Way analysis of variance (ANOVA) was performed and the Holm-Sidak method was used as a post-hoc test. Paired t-test was performed when compared S1 and S2. For all experiments, statistical significance was accepted at P<0.05.
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Figure S1
Representative raw data traces (A) and grouped data (B) to show heart rate responses to sympathetic nerve stimulation (SNS) at 1, 3, 5 and 7Hz with 100nM BNP compared to control (n=10). 100nM BNP did not significant decrease in SNS evoked changes in heart rate across all frequencies.
Figure S2 voltage relations in the presence and absence of 250 nmol/L BNP and after washing out. Wash off data were only recorded at -10mV as the quality of the recordings deteriorates over time. *P<0.05, paired t-test, n=3 neurons.
Figure S3
Western blot showing PDE2A.mCherry expression (127 KDa, A) and endogenous levels of PDE2A (100 KDa, B) in transduced empty (E) and Ad.PDE2A (P) stellate ganglia tissue (with anti-PDE2A antibody). Band optical density was normalized to that of β-actin (42 KDa). 
